|
|
||||||||
1 Cardiopulmonary Research Laboratory, Department of Surgery, and 2 Department of Pharmacology, Tulane University School of Medicine, 3 H. L. Laboratories, and 4 Department of Pharmacology, Louisiana State University School of Medicine, New Orleans, Louisiana 70112
This study investigated
the hypothesis that atrial natriuretic peptide (ANP) responses are
mediated by particulate guanylate cyclase in the pulmonary vascular bed
of the cat. When tone in the pulmonary vascular bed was raised
to a high steady level with the thromboxane mimic U-46619, injections
of ANP caused dose-related decreases in lobar arterial pressure. After
administration of HS-142-1, an ANP-A- and ANP-B-receptor antagonist,
vasodilator responses to ANP were reduced. The nitric oxide (NO)
synthase inhibitor
N
-nitro-L-arginine methyl ester
(L-NAME) enhanced ANP vasodilator responses, suggesting
that inhibition of NO modulates ANP responses. L-NAME
administration with constant 8-bromo-cGMP infusion attenuated the
increased vasodilator response to ANP, suggesting that supersensitivity to ANP occurs upstream to activation of a cGMP-dependent protein kinase. In pulmonary arterial rings, ANP produced concentration-related vasorelaxant responses with and without endothelium. Methylene blue,
L-NAME, or
N
-monomethyl-L-arginine did not
alter ANP vasorelaxant responses. These data show that ANP
supersensitivity observed in the intact pulmonary vascular bed is not
seen in isolated pulmonary arterial segments, suggesting that it may
only occur in resistance vessel elements. These results suggest that
ANP responses occur through activation of ANP-A and/or -B receptors in
an endothelium-independent manner and are modulated by NO in resistance
vessel elements in the pulmonary vascular bed of the cat.
lung; guanosine 3',5'-cyclic monophosphate; methylene blue; atrial
natriuretic peptide receptors; N
-monomethyl-L-arginine
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |